학술논문
Efficacy and safety of dupilumab in bullous pemphigoid: a retrospective multicentric study of 36 patients.
Document Type
Article
Author
Moghadam, Parna; Tancrede, Emmanuelle; Bouaziz, Jean-David; Kallout, Julien; Bedane, Christophe; Begon, Edouard; Bourgault-Villada, Isabelle; Calugareanu, Andreea; Dereure, Olivier; Jendoubi, Fatma; Pham-Ledard, Anne; Ingen-Housz-Oro, Saskia; Picard-Dahan, Catherine; Viguier, Manuelle; Mahevas, Thibault; Jachiet, Marie; Charvet, Estelle; Cassius, Charles; Alexandre, Marina; Lepelletier, Clémence
Source
Subject
*BULLOUS pemphigoid
*DUPILUMAB
*
Language
ISSN
0007-0963
Abstract
Among three patients with a history of psoriasis, two experienced a psoriasis flare-up during dupilumab treatment, and one required MTX retreatment for psoriasis along with dupilumab. Seven (19%) patients experienced relapse, always after treatment modification (TS withdrawal I n i = 4; steroid tapering I n i = 1; accidental dupilumab withdrawal I n i = 2). Https://doi.org/10.1093/bjd/ljad136 Dear Editor, Bullous pemphigoid (BP) is the most common autoimmune blistering disease in Europe.[1] A type 2 inflammatory response, including the production of interleukin (IL)-4, IL-5 and IL-13, is an important driver of BP pathogenesis, resulting in tissue damage.[2] More than 30% of patients with BP require second-line treatment that may be ineffective or poorly tolerated [methotrexate (MTX), mycophenolate mofetil (MMF)].[3] Dupilumab is an IL-4 -receptor antagonist. [Extracted from the article]